OBJECTIVE: • To systematically determine the effectiveness of biphasic calcium phosphate (BCP) as bone substitute materials (BSM) compared to other BSMs for new bone formation in dental implant treatment through a network meta-analysis (NMA). MATERIALS AND METHOD: • Following PRISMA-NMA guidelines, randomized controlled trials (RCTs) on lateral sinus augmentation and dental implants comparing BCP with other BSMs for histomorphometric new bone formation were included. Studies were retrieved from MEDLINE, Cochrane, Scopus, and Embase (up to November 2024), with quality assessed via the Cochrane risk of bias 2 (RoB2.0) tool. Analysis included direct and network meta-analyses using a random-effects model, with SUCRA scores determining treatment rankings. The PROSPERO registration number was CRD42024607526. RESULTS: • Of 268 studies, 11 met criteria, covering 283 patients and 362 sinus augmentations using autografts (AB), allografts (AL), beta tricalcium phosphate (TCP), BCP, and xenografts (Xeno). NMA showed AB resulted in 12.33% more new bone formation than BCP (95% CI: 10.74, 13.93), with AL showing 5.14% more (95% CI: 3.33, 6.95). Xeno showed 4.14% less bone formation than BCP (95% CI: -6.38, -1.90). AB ranked highest for new bone formation, followed by AL, BCP, TCP, and Xeno. Residual graft material was highest in Xeno (6.21%; 95% CI: 2.81, 9.61). CONCLUSION: • BCP demonstrated sufficient new bone formation, outperforming xenografts in both bone formation and residual graft material. While autografts and allografts exhibited superior bone regeneration, BCP remains an effective option for bone augmentation treatments.